Oncopeptides is a global biotech company, founded in Sweden, focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient lives.
On August 7, 2023, Oncopeptides announced that the Board of Directors has appointed Sofia Heigis as Chief Executive Officer, CEO, of Oncopeptides and replaces Monica Shaw. These changes are effective immediately.
Multiple myeloma is a cancer of the bone marrow that results in production of abnormal blood plasma cells. The disease is linked to substantial morbidity and mortality, and there is currently no cure. Patients being treated for multiple myeloma will experience symptom free periods, but they will relapse as the disease develops resistance to the treatment.
Below is a link to our global press releases from Oncopeptides AB (publ). This link takes you to our global website.
Fachinformation Pepaxti®
Download